^
    3d
    Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective Study. (PubMed, Cancer Res Treat)
    Pre-emptive treatment with antiemetics are required to manage early-phase NINV during niraparib maintenance therapy in patients with risk factors. Additional larger studies are needed to confirm these findings and to develop optimal preventive strategies for NINV.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Zejula (niraparib)
    3d
    N-Plus: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (clinicaltrials.gov)
    P2, N=640, Recruiting, North Eastern German Society of Gynaecological Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    carboplatin • Zejula (niraparib)
    6d
    PLATPARP: A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer with DNA Repair Defects (clinicaltrials.gov)
    P2, N=12, Completed, Abramson Cancer Center at Penn Medicine | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • HDAC2 (Histone deacetylase 2)
    |
    Zejula (niraparib)
    6d
    A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=320, Not yet recruiting, LaNova Medicines Limited
    New P1/2 trial • Combination therapy • Metastases
    |
    carboplatin • docetaxel • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • Zejula (niraparib)
    10d
    Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Washington | Trial primary completion date: Sep 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    UW-Oncoplex™
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    10d
    Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC (clinicaltrials.gov)
    P2, N=152, Not yet recruiting, VA Office of Research and Development
    New P2 trial
    |
    temozolomide • Zejula (niraparib) • Zepzelca (lurbinectedin)
    20d
    iNNOVATE: Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Virginia Commonwealth University | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial primary completion date • Metastases
    |
    Nerlynx (neratinib) • Zejula (niraparib)
    21d
    NADIR: Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, NRG Oncology | Trial primary completion date: Aug 2025 --> Jul 2024
    Trial primary completion date
    |
    Zejula (niraparib)
    21d
    Side effect management algorithms for niraparib/abiraterone acetate in prostate cancer. (PubMed, Can J Urol)
    These algorithms are intended to provide practical assistance to Canadian clinicians managing the most common AEs encountered with the novel combination, niraparib/AA+P, for mCRPC.
    Journal • Adverse events • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Zejula (niraparib) • abiraterone acetate • prednisone
    26d
    Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study. (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Pomeranian Medical University Szczecin | Not yet recruiting --> Recruiting
    Enrollment open • HEOR • Real-world evidence • Real-world • Metastases
    |
    Zejula (niraparib)
    27d
    Niraparib in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation
    |
    Zejula (niraparib)
    27d
    Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis. (PubMed, World J Surg Oncol)
    Our retrospective study demonstrates that PARP inhibitor maintenance therapy, including olaparib and niraparib, significantly prolongs PFS in patients with PSR epithelial ovarian, tubal, or primary peritoneal cancer, These findings support the broad utilization of PARP inhibitors as a standard maintenance therapy for PSR epithelial ovarian cancer irrespective of BRCA mutation status.
    Retrospective data • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Zejula (niraparib)
    1m
    ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Haider Mahdi | N=26 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    Zejula (niraparib) • ZEN-3694
    1m
    Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) (clinicaltrials.gov)
    P1, N=141, Recruiting, GlaxoSmithKline | Suspended --> Recruiting | Trial completion date: Apr 2029 --> May 2030 | Trial primary completion date: Sep 2028 --> Oct 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    1m
    PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD/E axis in ovarian cancer. (PubMed, J Immunother Cancer)
    PARPis induce a specific type of ICD called pyroptosis via TNF-caspase 8-GSDMD/E axis, resulting in an inflamed TIME and augmentation of tumor-targeting immune responses. These findings deepen our understanding of PARPis activities and point toward a promising avenue for synergizing PARPis with immunotherapeutic interventions.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • CASP8 (Caspase 8) • GSDME (Gasdermin E)
    |
    HRD
    |
    Zejula (niraparib)
    1m
    High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer (SITC 2024)
    Background TOPACIO was a phase I/II study evaluating the PARP inhibitor (PARPi) niraparib in combination with the anti-PD-1 antibody pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer (TNBC, n=55), irrespective of BRCA mutation status. The study protocol and/or other relevant documents received central approval by the Dana-Farber institutional review board and/or relevant competent authorities at each site. All patients supplied written informed consent for their participation in the study.
    BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset) • CD163 (CD163 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD68 (CD68 Molecule)
    |
    BRCA wild-type • BRCA mutation • PTPRC expression
    |
    nCounter® Breast Cancer 360™ Panel • nCounter® PanCancer IO 360™ Panel
    |
    Keytruda (pembrolizumab) • Zejula (niraparib)
    2ms
    Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review. (PubMed, Cureus)
    PARP inhibitors, such as olaparib, niraparib, or rucaparib, provide considerable benefits regarding progression-free survival expansion and overall outcomes improvement in first-line maintenance and recurrent settings. Ongoing clinical trials and future potential for personalized therapy approaches using PARP inhibitors for advanced ovarian cancer are also highlighted. However, despite these drugs' phenomenal ability to revolutionize treatment protocols for such cancer types, several challenges remain: toxicity management, cost, and development of resistance will require more research to optimize their use or broaden patient populations who can benefit from them.
    Review • Journal • BRCA Biomarker • PARP Biomarker • Metastases
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib)
    2ms
    Isoxazole compounds: Unveiling the synthetic strategy, in-silico SAR & toxicity studies and future perspective as PARP inhibitor in cancer therapy. (PubMed, Eur J Med Chem)
    PARP inhibitors, such as Olaparib, Rucaparib, Niraparib, and Talazoparib have been approved in a number of cancers including BRCA 1/BRCA2 associated malignancies although there are many difficulties as therapeutical resistance. It emphasizes that isoxazole-based PARP inhibitors compounds could be novel anti-cancer drugs. Through this review, we hope to grow a curiosity in additional explorations of isoxazole-based PARP inhibitors and their applications in the trends of novel insights towards precision cancer therapy.
    Review • Journal
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib)
    2ms
    Niraparib Enhances and Synergizes with Ganglioside GD2 to Potentiate its Inhibitory Effect on Bladder Cancer Cells. (PubMed, Comb Chem High Throughput Screen)
    Niraparib combined with a GD2-specific antibody exerted a more prominent inhibitory effect on BCa.
    Journal • PARP Biomarker
    |
    CDH1 (Cadherin 1) • VIM (Vimentin)
    |
    CDH1 expression • VIM expression
    |
    Zejula (niraparib)
    2ms
    PRIMA: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (clinicaltrials.gov)
    P3, N=733, Active, not recruiting, Tesaro, Inc. | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    Zejula (niraparib)
    2ms
    PAVO: Niraparib in the Treatment of Patients with Advanced PALB2 Mutated Tumors (clinicaltrials.gov)
    P2, N=22, Terminated, Tempus AI | Active, not recruiting --> Terminated; Recruitment challenges
    Trial termination
    |
    PALB2 mutation
    |
    Zejula (niraparib)
    2ms
    CHANGEABLE: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=37, Completed, Fudan University | Recruiting --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • BAP1 (BRCA1 Associated Protein 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCF (FA complementation group F) • WRN (WRN RecQ Like Helicase) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • PTEN mutation + HR positive • CHEK1 expression • HER-2 negative + HR positive + BRCA mutation
    |
    Herceptin (trastuzumab) • Zejula (niraparib) • Puyouheng (pucotenlimab)
    2ms
    ASCLEPIuS: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=102, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DRD (DNA Repair Deficiency)
    |
    DDR • DRD
    |
    Zejula (niraparib) • abiraterone acetate • leuprolide acetate for depot suspension
    2ms
    Niraparib Maintenance Treatment in Patients with Newly Diagnosed Advanced Platinum- Sensitive, OC. the First Poland RWE Study. (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Pomeranian Medical University Szczecin
    New trial • HEOR • Real-world evidence • Real-world • Metastases
    |
    Zejula (niraparib)
    2ms
    Molecular mechanism of PARP inhibitor resistance. (PubMed, Oncoscience)
    Currently, four PARPi including Olaparib, Rucaparib, Niraparib, and Talazoparib have been developed and greatly improved clinical outcomes in cancer patients. However, accumulating evidences suggest that required or de novo resistance emerged. In this review, we discuss the molecular mechanisms leading to PARPi resistances and review the potential strategies to overcome PARPi resistance.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib)
    2ms
    Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. (PubMed, Eur Urol)
    Treatment with niraparib + AAP maintained HRQoL with minimal side-effect bother reported by most patients with BRCA+ mCRPC. Differences between treatment groups in time to pain deterioration did not meet conventional levels of statistical significance. The MAGNITUDE trial is registered on ClinicalTrials.gov as NCT03748641.
    P3 data • Journal • BRCA Biomarker • PARP Biomarker • Patient reported outcomes • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation
    |
    Zejula (niraparib) • abiraterone acetate • prednisone
    2ms
    MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
    P1/2, N=645, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> May 2026
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827
    2ms
    A Phase I Study of Niraparib Administered Concurrently with Postoperative RT in Triple Negative Breast Cancer Patients (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: May 2022 --> Dec 2024
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Zejula (niraparib)
    2ms
    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. (PubMed, J Clin Oncol)
    Combining atezolizumab with CT and maintenance niraparib for late-relapsing recurrent ovarian cancer did not significantly improve PFS or the ORR.
    P3 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • BRCA mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • Zejula (niraparib)
    2ms
    HOTT: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (clinicaltrials.gov)
    P3; Trial completion date: Aug 2038 --> Aug 2034 | Trial primary completion date: Aug 2033 --> Aug 2029
    Trial completion date • Trial primary completion date • Surgery
    |
    Myriad myChoice® CDx
    |
    cisplatin • Zejula (niraparib)
    2ms
    Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial. (PubMed, Ann Oncol)
    In patients with newly diagnosed aOC at high risk of recurrence, there was no difference in OS between treatment arms. In the HRd population, patients alive at 5 years were twice as likely to be progression free with niraparib treatment than placebo. Long-term safety remained consistent with the established niraparib safety profile.
    Journal • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Zejula (niraparib)
    2ms
    PARPi-PANC: Niraparib As First Line Therapy with Metastatic Homologous Repair-deficient Pancreatic Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Centre Leon Berard | N=28 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • FANCD2 (FA Complementation Group D2)
    |
    HRD signature
    |
    Zejula (niraparib)
    2ms
    A Study of Niraparib in Combination with Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) (clinicaltrials.gov)
    P1/2, N=73, Not yet recruiting, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    New P1/2 trial • Combination therapy
    |
    Verzenio (abemaciclib) • Zejula (niraparib)
    2ms
    LUNAAR: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Baptist Health South Florida | N=30 --> 0 | Trial completion date: Jul 2028 --> Oct 2028 | Initiation date: Jul 2024 --> Oct 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2026 --> Oct 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • Metastases
    |
    Zejula (niraparib) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Akeega (abiraterone/niraparib)
    2ms
    An Emulated Target Trial Case Study of Real-World Overall Survival With Second-Line Maintenance Niraparib Versus Active Surveillance in Patients With Recurrent Ovarian Cancer. (PubMed, Pharmacoepidemiol Drug Saf)
    This real-world study provides supportive evidence of an OS benefit for patients with BRCAwt recurrent OC who received 2LM niraparib monotherapy compared with those whose care was managed with AS. The analytic strategies implemented were useful in minimizing immortal time bias and measured confounding.
    Clinical • Retrospective data • Journal • Real-world evidence • Real-world
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type
    |
    Zejula (niraparib)
    2ms
    Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study. (PubMed, J Gynecol Oncol)
    The long-term efficacy and safety profile of niraparib was consistent with previous findings in the equivalent population in non-Japanese patients. No new safety signals were identified.
    P2 data • Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    Zejula (niraparib)
    2ms
    Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study. (PubMed, Int J Gynecol Cancer)
    In this real-world study of patients receiving niraparib-bevacizumab first-line maintenance, the majority of whom had HRp/HR status unknown, the median time to next treatment was consistent with observed progression-free survival in patients with similar HR status in the OVARIO study.
    Journal • Real-world evidence • Real-world
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type
    |
    Avastin (bevacizumab) • Zejula (niraparib)
    3ms
    OVARIO: A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=105, Completed, Tesaro, Inc. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    Avastin (bevacizumab) • Zejula (niraparib)
    3ms
    Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. (PubMed, Cancers (Basel))
    Glioblastoma (GBM) is an immunologically cold tumor, but several immunotherapy-based strategies show promise, including the administration of ex vivo expanded and activated cytotoxic gamma delta T cells. Gamma delta T cell-mediated cytotoxicity at a 10:1 effector-to-target ratio was significantly increased upon pretreatment of cells derived from a GBM PDX with TMZ and niraparib in comparison to the control or either drug alone. Together, these data demonstrate that the combination of PARP inhibition, DNA alkylation, and gamma delta T cell therapy has the potential for the treatment of GBM.
    Journal • PARP Biomarker • IO biomarker
    |
    ULBP1 (UL16 Binding Protein 1)
    |
    temozolomide • Zejula (niraparib) • INB-200
    3ms
    ONC-2022-001: Niraparib and Temozolomide in Patients Glioblastoma (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, Armando Santoro, MD | Initiation date: Mar 2024 --> Sep 2024
    Trial initiation date
    |
    temozolomide • Zejula (niraparib)
    3ms
    ANITA: Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P3, N=417, Completed, Grupo Español de Investigación en Cáncer de Ovario | Trial completion date: Jan 2024 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Aug 2024 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset)
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • Zejula (niraparib) • pegylated liposomal doxorubicin
    3ms
    Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (clinicaltrials.gov)
    P1/2, N=67, Completed, Fundacion CRIS de Investigación para Vencer el Cáncer | Active, not recruiting --> Completed | N=20 --> 67 | Trial completion date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2024 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Zejula (niraparib) • Cabometyx (cabozantinib tablet)